GlobeNewswire Inc | Jan 26, 2022 07:30AM EST

January 26, 2022

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd.(Nasdaq: PYPD) (PolyPid or the Company), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets onWednesday, February 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Timeto discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, February 9, 2022Time: 8:30 AM Eastern TimeUnited States: +1 877-870-9135Israel: +972 1809 213-985International: +44 (0) 2071 928338Conference ID: 6092321Webcast: https://edge.media-server.com/mmc/p/fxz7727t

AboutPolyPid

PolyPid Ltd.(Nasdaq:PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPids proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPids lead product candidate D-PLEX100is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).

For additional company information, please visitpolypid.comand follow us onTwitterandLinkedIn.

Contacts:PolyPid, Ltd.Dikla Czaczkes AkselbradEVP & CFOTel: +972-747195700

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com

Media:Nechama FeuersteinFINN Partners551-444-0784Nechama.Feuerstein@finnpartners.com